Company to Provide Investor Update During Virtual Investor Conference on August 19 at 2:00pm ET (Details Below); Management Available for Virtual 1×1 Meetings SARASOTA, Fla., Aug. 13, 2020/PRNewswire/ - INVO Bioscience, Inc. (OTCQB: INVO), a medical device company focused on creating alternative treatments for patients diagnosed with infertility and developers of INVOcell®, the world`s only in vivo Intravaginal Culture System, today announced financial results for the quarter ended June 30, 2020. Recent Highlights Similar to the first quarter of 2020, revenues of $246,072in the second quarter of 2020 continued to be impacted by COVID-19. However, with many fertility clinics reopening along...
|
